Family Medicine

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Condition:   Diarrhea-predominant Irritable Bowel Syndrome
Interventions:   Drug: BOS-589;   Drug: Placebo
Sponsor:   Boston Pharmaceuticals
Recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 6, 2019Comments OffBOS589 | Bowel | Diarrheapredominant | Efficacy | Evaluate | IBSD | Irritable | Patients | Safety | Study | Syndrome | Tolerability | Treatment
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 3, 2019Comments OffCancer | Care | Cell | Lung | LungMAP | NonMatch | NonSmall | Patients | Pembrolizumab | Ramucirumab | Recurrent | Stage | Standard | Treating | Treatment | Trial | Versus
Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (CLARITY-2)

Condition:   Adjunctive Treatment of Major Depressive Disorder
Interventions:   Drug: Pimavanserin;   Drug: Placebo
Sponsor:   ACADIA Pharmaceuticals Inc.
Recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 31, 2019Comments OffAdjunctive | Antidepressant | CLARITY2 | Depressive | Disorder | Efficacy | Evaluate | Inadequate | Major | Pimavanserin | Response | Safety | Study | Subjects | Treatment
Beyond the Lung Cancer Diagnosis: Leveraging the Oncology Clinic Setting for Actively Smoking Family Members

Condition:   Lung Cancer
Interventions:   Behavioral: Digital-based support;   Behavioral: Traditional-based support + Nicotine replacement therapy (NRT)
Sponsor:   Indiana University
Not yet recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 30, 2019Comments OffActively | Beyond | Cancer | Clinic | Diagnosis | Family | Leveraging | Lung | Members | Oncology | Setting | Smoking
Prenatal Genetic Diagnosis by Genomic Sequencing

Condition:   Fetal Structural Anomalies
Intervention:   Diagnostic Test: Prenatal Genomic Sequencing
Sponsors:   Columbia University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Baylor College of Medicine;   University of North Carolina;   The George Washington University Biostatistics Center;   Oregon Health and Science University
Recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 24, 2019Comments OffDiagnosis | Genetic | Genomic | Prenatal | Sequencing
Patient and Caregiver-Centered Diabetes Telemanagement Program for Hispanic/Latino Patients

Conditions:   Type 2 Diabetes Mellitus;   Type2 Diabetes
Interventions:   Other: Comprehensive Outpatient Management;   Behavioral: Diabetes Telemonitoring
Sponsors:   Northwell Health;   Patient-Centered Outcomes Research Institute
Not yet recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 23, 2019Comments OffCaregiverCentered | Diabetes | Hispanic/Latino | Patient | Patients | Program | Telemanagement
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel TSPO Radioligand

Condition:   Dementia
Interventions:   Drug: 11C-ER176;   Drug: 11C-PIB
Sponsor:   National Institute of Mental Health (NIMH)
Not yet recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 22, 2019Comments OffDiseases | Imaging | Neurodegenerative | Neuroinflammation | Novel | Radioligand | TSPO